Showing results (11-20 of 207) with videos related to
Sort By:
Pageof 21
American Journal of Hypertension|July 18, 2002
Recent landmark clinical trials: how do they modify the therapeutic paradigm?Murray EpsteinKidney International Supplements|May 9, 2022
Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohortsMurray EpsteinDiabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 16, 2022
A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021: A Paradigm ShiftMurray EpsteinNature Clinical Practice. Nephrology|November 5, 2008
Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney diseaseMurray EpsteinChemsuschem|May 21, 2010
Ceria-based solid catalysts for organic chemistryLaurence Vivier, Daniel DuprezExpert Review of Cardiovascular Therapy|November 13, 2013
Prehypertension and the cardiometabolic syndrome: pathological and clinical consequencesDaniel Duprez, Aigerim ToleuovaExpert Opinion on Pharmacotherapy|May 17, 2016
Recent advances in pharmacological treatments of hyperkalemia: focus on patiromerMurray Epstein, Bertram PittCurrent Hypertension Reports|May 11, 2002
The use of calcium antagonists in the treatment of hypertensive persons with kidney diseaseSheldon Tobe, Murray EpsteinJournal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|April 10, 2003
Cyclooxygenase-2 expression and function in renal pathophysiologyRadko Komers, Murray EpsteinThe American Journal of Medicine|January 3, 2022
Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021Peter Rossing, Murray EpsteinPageof 21